Literature DB >> 25585532

Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of ageing.

Robert H Pietrzak1, Yen Ying Lim2, David Ames3, Karra Harrington4, Carolina Restrepo4, Ralph N Martins5, Alan Rembach4, Simon M Laws5, Colin L Masters4, Victor L Villemagne6, Christopher C Rowe7, Paul Maruff8.   

Abstract

Memory changes in preclinical Alzheimer's disease (AD) are often characterized by heterogenous trajectories. However, data regarding the nature and determinants of predominant trajectories of memory changes in preclinical AD are lacking. We analyzed data from 333 cognitively healthy older adults who participated in a multicenter prospective cohort study with baseline and 18-, 36-, and 54-month follow-up assessments. Latent growth mixture modeling revealed 3 predominant trajectories of memory change: a below average, subtly declining memory trajectory (30.9%); a below average, rapidly declining memory trajectory (3.6%); and an above average, stable memory trajectory (65.5%). Compared with the stable memory trajectory, high Αβ (relative risk ratio [RRR] = 2.1), and lower Mini-Mental State Examination (RRR = 0.6) and full-scale IQ (RRR = 0.9) scores were independently associated with the subtly declining memory trajectory; and high Αβ (RRR = 8.3), APOE ε4 carriage (RRR = 6.1), and greater subjective memory impairment (RRR = 1.2) were independently associated with the rapidly declining memory trajectory. Compared with the subtly declining memory trajectory group, APOE ε4 carriage (RRR = 8.4), and subjective memory complaints (RRR = 1.2) were associated with a rapidly declining memory trajectory. These results suggest that the preclinical phase of AD may be characterized by 2 predominant trajectories of memory decline that have common (e.g., high Αβ) and unique (e.g., APOE ε4 genotype) determinants. Published by Elsevier Inc.

Entities:  

Keywords:  APOE; Alzheimer's disease; Aβ; Memory; Trajectories

Mesh:

Substances:

Year:  2014        PMID: 25585532     DOI: 10.1016/j.neurobiolaging.2014.12.015

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  41 in total

Review 1.  Redox proteomics and amyloid β-peptide: insights into Alzheimer disease.

Authors:  D Allan Butterfield; Debra Boyd-Kimball
Journal:  J Neurochem       Date:  2018-11-27       Impact factor: 5.372

2.  Trajectories of depressive and anxiety symptoms in older adults: a 6-year prospective cohort study.

Authors:  Sophie E Holmes; Irina Esterlis; Carolyn M Mazure; Yen Ying Lim; David Ames; Stephanie Rainey-Smith; Chris Fowler; Kathryn Ellis; Ralph N Martins; Olivier Salvado; Vincent Doré; Victor L Villemagne; Christopher C Rowe; Simon M Laws; Colin L Masters; Robert H Pietrzak; Paul Maruff
Journal:  Int J Geriatr Psychiatry       Date:  2017-07-24       Impact factor: 3.485

3.  Effect of common neuropathologies on progression of late life cognitive impairment.

Authors:  Lei Yu; Patricia A Boyle; Sue Leurgans; Julie A Schneider; Richard J Kryscio; Robert S Wilson; David A Bennett
Journal:  Neurobiol Aging       Date:  2015-04-22       Impact factor: 4.673

Review 4.  The Neurobiology and Age-Related Prevalence of the ε4 Allele of Apolipoprotein E in Alzheimer's Disease Cohorts.

Authors:  Amy L Heffernan; Cameron Chidgey; Po Peng; Colin L Masters; Blaine R Roberts
Journal:  J Mol Neurosci       Date:  2016-08-06       Impact factor: 3.444

5.  Race, APOEɛ4, and Long-Term Cognitive Trajectories in a Biracial Population Sample.

Authors:  Kumar B Rajan; Elizabeth A McAninch; Robert S Wilson; Jennifer Weuve; Lisa L Barnes; Denis A Evans
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

6.  Sleep moderates the relationship between amyloid beta and memory recall.

Authors:  Kristine A Wilckens; Dana L Tudorascu; Beth E Snitz; Julie C Price; Howard J Aizenstein; Oscar L Lopez; Kirk I Erickson; Brian J Lopresti; Charles M Laymon; Davneet Minhas; Chester A Mathis; Daniel J Buysse; William E Klunk; Ann D Cohen
Journal:  Neurobiol Aging       Date:  2018-07-26       Impact factor: 4.673

7.  Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials.

Authors:  Joshua D Grill; Yan Zhou; David Elashoff; Jason Karlawish
Journal:  Neurobiol Aging       Date:  2015-11-22       Impact factor: 4.673

8.  Simultaneous quantitative susceptibility mapping and Flutemetamol-PET suggests local correlation of iron and β-amyloid as an indicator of cognitive performance at high age.

Authors:  J M G van Bergen; X Li; F C Quevenco; A F Gietl; V Treyer; R Meyer; A Buck; P A Kaufmann; R M Nitsch; P C M van Zijl; C Hock; P G Unschuld
Journal:  Neuroimage       Date:  2018-03-13       Impact factor: 6.556

9.  Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.

Authors:  Murat Bilgel; Yang An; Jessica Helphrey; Wendy Elkins; Gabriela Gomez; Dean F Wong; Christos Davatzikos; Luigi Ferrucci; Susan M Resnick
Journal:  Brain       Date:  2018-08-01       Impact factor: 13.501

10.  Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community.

Authors:  Ronald C Petersen; Heather J Wiste; Stephen D Weigand; Walter A Rocca; Rosebud O Roberts; Michelle M Mielke; Val J Lowe; David S Knopman; Vernon S Pankratz; Mary M Machulda; Yonas E Geda; Clifford R Jack
Journal:  JAMA Neurol       Date:  2016-01       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.